Gilead’s Trodelvy® Shows Promising Results for Metastatic TNBC
Trodelvy® has demonstrated a 38% reduction in disease progression risk for metastatic TNBC patients, according to recent ASCENT-03 study findings.
Pfizer’s BRAFTOVI and MEKTOVI Combination Shows Long-Term Survival
Pfizer's BRAFTOVI® and MEKTOVI® demonstrate significant long-term survival benefits for lung cancer patients, as revealed in the latest clinical trial findings.
DATROWAY® Shows Significant Survival Benefit in Breast Cancer Patients
Daiichi Sankyo and AstraZeneca’s DATROWAY® improves survival in metastatic triple negative breast cancer patients lacking immunotherapy options, according to new trial data.
Delcath Systems Unveils Promising Results from CHOPIN Clinical Trial
Delcath Systems' CHOPIN Trial shows significant progress in treating liver cancer with innovative therapy options for patients.
Delcath Systems Reports Third Quarter 2025 Financial Outcomes
Delcath Systems shares preliminary financial results for Q3 2025, revealing revenue insights and future growth expectations in liver cancer treatments.
Aurion Biotech’s AURN001 Trial Shows Promising Results for Vision Restoration
Aurion Biotech reports success in its AURN001 trial, advancing towards pivotal Phase 3 studies for corneal endothelial disease treatment.
Houston’s Energy Day Festival Celebrates 13 Years of STEM Engagement
The 13th Annual Energy Day Festival in Houston showcased STEM opportunities for students, featuring interactive exhibits and a focus on the energy sector.
Merck’s KEYTRUDA and Padcev Show Promising Results in Bladder Cancer
Merck's KEYTRUDA and Padcev combination therapy reduces mortality by 50% in muscle-invasive bladder cancer, a significant advance for patients.
ENHERTU® Shows Promising Results for HER2-Positive Breast Cancer
In a recent trial, ENHERTU® demonstrated a 67% pathologic complete response in high-risk HER2-positive early-stage breast cancer patients, paving the way for new treatment standards.
ENHERTU® Shows 53% Reduction in Recurrence Risk for HER2+ Breast Cancer
The DESTINY-Breast05 trial highlights ENHERTU®'s effectiveness in reducing disease recurrence risk in high-risk HER2-positive breast cancer patients.
Merck’s KEYTRUDA® Shows Progress in Treating Ovarian Cancer
New data from the KEYNOTE-B96 trial reveals KEYTRUDA® combined with chemotherapy may improve survival for certain ovarian cancer patients.
ENHERTU® Shows Promising Results in HER2 Positive Breast Cancer
The DESTINY-Breast11 trial reveals ENHERTU® can achieve a 67% pathologic complete response in high-risk HER2 positive breast cancer patients before surgery.
ENHERTU® Shows 53% Reduction in Disease Recurrence in Breast Cancer
ENHERTU® significantly lowers disease recurrence risk in HER2-positive early breast cancer patients, according to the latest DESTINY-Breast05 trial results.
Akbank’s Alper Bektaş Highlights Strategic Support for SMEs
Alper Bektaş from Akbank emphasizes comprehensive support for entrepreneurs in their investment journeys and strategic consulting services.
Infrrd Unveils Ally: A Revolutionary AI Solution for Mortgage Auditing
Infrrd launches Ally, an innovative AI workforce designed to transform mortgage auditing, set to debut at a live webinar on October 29, 2025.
Founder Hasan Ateş Budak Leads Dior Media in Redefining Dubai’s Real Estate Branding
Businessman Hasan Ateş Budak Leads Trusted Collaboration in Dubai: Dior Media Makes a Difference in Broker…
Rosen Law Firm Calls on Snap Inc. Shareholders Amid Class Action
Snap Inc. stockholders facing significant losses urged to participate in class action against the company for alleged misleading information on business performance.